RU2003118411A - Кристаллические производные 1-метилкарбапенема - Google Patents

Кристаллические производные 1-метилкарбапенема

Info

Publication number
RU2003118411A
RU2003118411A RU2003118411/04A RU2003118411A RU2003118411A RU 2003118411 A RU2003118411 A RU 2003118411A RU 2003118411/04 A RU2003118411/04 A RU 2003118411/04A RU 2003118411 A RU2003118411 A RU 2003118411A RU 2003118411 A RU2003118411 A RU 2003118411A
Authority
RU
Russia
Prior art keywords
methylcarbapenem
derivative
crystalline form
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
RU2003118411/04A
Other languages
English (en)
Inventor
Исао КАВАМОТО (JP)
Исао Кавамото
Ясуо СИМОДЗИ (JP)
Ясуо СИМОДЗИ
Хироси ФУКУХАРА (JP)
Хироси ФУКУХАРА
Original Assignee
Санкио Компани, Лимитед (Jp)
Санкио Компани, Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санкио Компани, Лимитед (Jp), Санкио Компани, Лимитед filed Critical Санкио Компани, Лимитед (Jp)
Publication of RU2003118411A publication Critical patent/RU2003118411A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (5)

1. Производное 1-метилкарбапенема формулы (I-1) в кристаллической форме:
Figure 00000001
2. Производное 1-метилкарбапенема формулы (I) или его фармацевтически приемлемая соль в кристаллической форме:
Figure 00000002
отличающееся тем, что кристаллическая форма обнаруживает основные пики при межплоскостных расстояниях d=6,65, 5,68, 4,86, 4,57 и 4,03 A на порошковой рентгенограмме, полученной с Cu Kα облучением λ=1,54 A, основные пики имеют интенсивность не меньше, чем 74 (которая является относительной интенсивностью, когда интенсивность пика при 4,57 A оценивают как 100).
3. Фармацевтическая композиция для профилактики или лечения бактериальных инфекций, содержащая кристаллическую форму производного 1-метилкарбапенема или его фармацевтически приемлемой соли по любому из п.п.1, 2 в качестве активного ингредиента.
4. Производное 1-метилкарбапенема или его фармацевтически приемлемая соль по п.1 или 2 в качестве активного ингредиента для получения лекарственного средства для профилактики или лечения бактериальных инфекционных заболеваний.
5. Способ профилактики или лечения бактериальных инфекционных заболеваний, который включает введение теплокровному животному, нуждающемуся в такой профилактике или лечении, фармакологически эффективного количества кристаллической формы производного 1-метилкарбапенема или его фармацевтически приемлемой соли по п.1 или 2.
RU2003118411/04A 1999-07-06 2003-06-18 Кристаллические производные 1-метилкарбапенема RU2003118411A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11/191368 1999-07-06
JP19136899 1999-07-06

Publications (1)

Publication Number Publication Date
RU2003118411A true RU2003118411A (ru) 2004-12-20

Family

ID=16273433

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2002100058/04A RU2214411C2 (ru) 1999-07-06 2000-07-06 Кристаллические производные 1-метилкарбапенема
RU2003118411/04A RU2003118411A (ru) 1999-07-06 2003-06-18 Кристаллические производные 1-метилкарбапенема

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2002100058/04A RU2214411C2 (ru) 1999-07-06 2000-07-06 Кристаллические производные 1-метилкарбапенема

Country Status (21)

Country Link
US (3) US20020128254A1 (ru)
EP (1) EP1193269A4 (ru)
JP (1) JP3476420B2 (ru)
KR (1) KR100750552B1 (ru)
CN (2) CN100360530C (ru)
AU (1) AU758190B2 (ru)
BR (1) BR0012253A (ru)
CA (1) CA2378483C (ru)
CZ (1) CZ20014731A3 (ru)
HK (1) HK1044768A1 (ru)
HU (1) HUP0202255A3 (ru)
IL (2) IL147214A0 (ru)
MX (1) MXPA02000061A (ru)
NO (1) NO327786B1 (ru)
NZ (1) NZ516310A (ru)
PL (1) PL352296A1 (ru)
RU (2) RU2214411C2 (ru)
TR (2) TR200403436T2 (ru)
TW (1) TWI250160B (ru)
WO (1) WO2001002401A1 (ru)
ZA (1) ZA200110413B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760163B2 (en) 1999-04-06 2003-05-08 Sankyo Company Limited Alpha-substituted carboxylic acid derivatives
US7041660B2 (en) * 1999-07-06 2006-05-09 Sankyo Company, Limited Crystalline 1-methylcarbapenem derivatives
WO2001023393A1 (fr) * 1999-09-30 2001-04-05 Otsuka Kagaku Kabushiki Kaisha Cristaux obtenus a partir d'un derive de 3-cepheme et methode de preparation
WO2001097851A2 (en) 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
KR100451672B1 (ko) * 2001-06-05 2004-10-08 한미약품 주식회사 결정성 세프디니르 산부가염, 이의 제조방법 및 이를이용한 세프디니르의 제조방법
US20040198973A1 (en) * 2001-08-13 2004-10-07 Tsujii Masahiko Process for preparation of carbapenem antibiotics
ES2368997T3 (es) * 2001-09-26 2011-11-24 Merck Sharp & Dohme Corp. Procedimiento de fabricación de compuestos de carbapenem.
HRP20040264B1 (en) * 2001-09-26 2012-07-31 Merck@Sharp@@@Dohme@Corp Process for making carbapenem compounds
ITMI20012364A1 (it) * 2001-11-09 2003-05-09 Antibioticos Spa Processo di sintesi della cefixima via alchil-o arilsolfonati
BRPI0413842A (pt) * 2003-08-25 2006-10-24 Sankyo Co composto de 1-metil-carbapenem ou um seu sal farmacologicamente aceitável, etanolato e tetra-hidrato de composto de 1-metil-carbapenem, processo para a preparação da forma cristalina, processo para a preparação de um tri-hidrato de etanolato de composto de 1-metil-carbapenem, tri-hidrato de etanolato de composto de 1-metil-carbapenem, composição farmacêutica para prevenir ou tratar infecções bacterianas, e, uso da forma cristalina
JP2005097278A (ja) * 2003-08-25 2005-04-14 Sankyo Co Ltd １−メチルカルバペネム化合物の結晶
WO2005118586A1 (en) * 2004-06-02 2005-12-15 Sandoz Ag Meropenem intermediate in crystalline form
WO2006101062A1 (ja) * 2005-03-22 2006-09-28 Daiichi Sankyo Company, Limited １－アルキルピロリジン構造を有するカルバペネム誘導体の製造方法
EP1877041A2 (en) 2005-04-29 2008-01-16 Cubist Pharmaceuticals, Inc. Therapeutic compositions
JPWO2006121151A1 (ja) * 2005-05-13 2008-12-18 第一三共株式会社 １−メチルカルバペネム化合物の結晶
CN101328179B (zh) * 2007-06-15 2011-01-12 山东轩竹医药科技有限公司 含有氧代氮杂环的巯基吡咯烷培南衍生物
CN101412717B (zh) * 2007-10-19 2011-01-12 山东轩竹医药科技有限公司 含有胍基烷酰胺基杂环的碳青霉烯衍生物
US20110054168A1 (en) * 2008-01-17 2011-03-03 Ayumu Kurimoto Method for preparing adenine compound
US20130079322A1 (en) * 2010-05-21 2013-03-28 Xuanzhu Pharama Co., Ltd. Crystalline of carbapenem derivative or its hydrate, preparation methods and uses thereof
US8822445B2 (en) * 2010-06-03 2014-09-02 Xuanzhu Pharma Co., Ltd. Crystalline form of carbapenem derivative or its hydrates and preparation methods and uses thereof
CN105102424B (zh) * 2013-01-15 2020-09-11 默克专利股份公司 用于治疗关节病的酰基胍类

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4748238A (en) 1984-03-14 1988-05-31 Merck & Co., Inc. Crystalline 1R,5S,6S,8R-1-methyl-2-(N,N-dimethylcarbamimidoylmethylthio)-6-(1-hydroxyethyl)-1-carbapen-2-em-3-carboxylic acid
US4713451A (en) 1984-04-09 1987-12-15 Merck & Co., Inc. Crystalline dimethyliminothienamycin
IE60588B1 (en) 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
US4866171A (en) 1987-04-11 1989-09-12 Lederle (Japan), Ltd. (1R,5S,6S)-2-[(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazolium-6-yl)]thio-6-[R-1-hydroxyethyl]-1-methyl-carbapenum-3-carboxylate
TW209220B (ru) * 1991-11-27 1993-07-11 Manyu Seiyaku Kk
EP0599512B1 (en) 1992-11-17 1999-03-24 Sankyo Company Limited Crystalline carbapenem derivative
JPH06336483A (ja) * 1993-05-26 1994-12-06 Banyu Pharmaceut Co Ltd アミノアルキルピロリジニルチオカルバペネム誘導体
JPH07291973A (ja) * 1994-04-27 1995-11-07 Banyu Pharmaceut Co Ltd 新規な２−ピロリジニルチオカルバペネム誘導体
JPH09110869A (ja) * 1995-10-23 1997-04-28 Lederle Japan Ltd カルバペネム化合物
CZ298246B6 (cs) 1995-12-21 2007-08-01 Sankyo Company Limited Deriváty 1-methylkarbapenu, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují
JP2955276B2 (ja) * 1997-06-19 1999-10-04 三共株式会社 １−メチルカルバペネム誘導体を含有する抗菌剤

Also Published As

Publication number Publication date
IL147214A0 (en) 2002-08-14
AU758190B2 (en) 2003-03-20
HK1044768A1 (zh) 2002-11-01
HUP0202255A2 (en) 2002-10-28
EP1193269A1 (en) 2002-04-03
US20030232803A1 (en) 2003-12-18
US20020128254A1 (en) 2002-09-12
KR100750552B1 (ko) 2007-08-20
NO20020030L (no) 2002-03-05
ZA200110413B (en) 2003-03-19
BR0012253A (pt) 2002-03-26
AU5848700A (en) 2001-01-22
CZ20014731A3 (cs) 2002-04-17
MXPA02000061A (es) 2002-07-02
CN101077869A (zh) 2007-11-28
HUP0202255A3 (en) 2003-10-28
KR20020022761A (ko) 2002-03-27
CA2378483A1 (en) 2001-01-11
TR200200100T2 (tr) 2002-05-21
CN1372560A (zh) 2002-10-02
JP3476420B2 (ja) 2003-12-10
IL147214A (en) 2009-12-24
CN100360530C (zh) 2008-01-09
TR200403436T2 (tr) 2005-03-21
TWI250160B (en) 2006-03-01
EP1193269A4 (en) 2003-05-28
NZ516310A (en) 2004-05-28
WO2001002401A1 (fr) 2001-01-11
NO327786B1 (no) 2009-09-21
NO20020030D0 (no) 2002-01-04
US6924279B2 (en) 2005-08-02
JP2001072681A (ja) 2001-03-21
PL352296A1 (en) 2003-08-11
US20030158174A1 (en) 2003-08-21
RU2214411C2 (ru) 2003-10-20
CA2378483C (en) 2008-09-16

Similar Documents

Publication Publication Date Title
RU2003118411A (ru) Кристаллические производные 1-метилкарбапенема
RU93058555A (ru) Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения или профилактики
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
WO2004029031A3 (en) Therapeutic piperazine compounds
RU94013439A (ru) Гетероциклические соединения, способ их получения, фармацевтическая композиция и способ лечения
EP1467970A4 (en) HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE
JP2005500357A5 (ru)
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
RU95122135A (ru) Комбинация для профилактики и лечения спида, фармацевтическая композиция на ее основе
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
SE9901573D0 (sv) New compounds
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
RU2003100507A (ru) Фармацевтические композиции
EA200000176A1 (ru) Применение физиологически приемлемых соединений, солей и комплексов ванадия
RU2002130247A (ru) Производные оксадиазола, обладающие противоопухолевым действием
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
TR199701497T1 (xx) Beyin �demini �nleyen terkip.
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
SE9901572D0 (sv) New compounds
RU98101105A (ru) Новое применение в медицинских целях
ES2034484T3 (es) El uso de oxidos de tiadiazol para la preparacion de una composicion farmaceutica para el tratamiento de desordenes de motilidad gastrointestinal.
RU2005131723A (ru) Лечение пролиферативных заболеваний производными эпотилона и излучением

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20050117